Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KLRA

Kailera Therapeutics Inc

May 26 • 04:00PM ET

21.57

+0.40 1.89 %

Healthcare • Biotechnology • USA • Mid • NASD

Today, 4:05 PMKailera advances obesity pipeline with positive new data and starts global Phase 3 KaiNETIC trial of ribupatide injection

Peers: NTLA TWST RXRX VERA BEAM

| Held by: VTI VB VBR VBK OZEM VXF VTWO VTWG VTWV TNXT

Index	-	P/E	-	EPS (ttm)	-	Insider Own	31.03%	Shs Outstand	129.54M	Perf Week	10.33%
Market Cap	2.79B	Forward P/E	-	EPS next Y	-3.55	Insider Trans	103.27%	Shs Float	89.34M	Perf Month	-4.01%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	12.18%	Short Float	2.19%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-153.84%	Inst Trans	25.07%	Short Ratio	1.96	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-0.61%	ROA	-	Short Interest	1.95M	Perf YTD	-17.04%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	28.23 -23.58%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	19.01 13.47%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.81% 7.51%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-3.85%	Beta	-	Target Price	42.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-6.04%	Rel Volume	0.49	Prev Close	21.17
Employees	145	LT Debt/Eq	-	Earnings	-	SMA200	-6.04%	Avg Volume	997.56K	Price	21.57
IPO	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	484,311	Change	1.89%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	William Blair	Outperform
May-12-26	Initiated	TD Cowen	Buy	$57
May-12-26	Initiated	Leerink Partners	Outperform	$36
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	Jefferies	Buy	$48
May-12-26	Initiated	Evercore ISI	Outperform

Today 04:02PM	Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates (GlobeNewswire)
May-13-26 07:30AM	Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire) -5.34%
May-12-26 12:50PM	Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity (Investor's Business Daily)
Apr-20-26 04:05PM	Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.35%

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

M.B.A.Mr. Ronald C. Renaud Jr.

M.S.Mr. Paul Douglas Burgess J.D.

Chief Commercial OfficerMs. Jamie Beth Coleman

Chief Financial OfficerMr. Douglas W. Pagan M.B.A.

Vice President of Corporate Communications & Investor RelationsMaura Gavaghan

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RTW INVESTMENTS, LP	10% Owner	Apr 20 '26	Buy	16.00	500,000	8,000,000	10,776,820	Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:10 PM
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:08 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:01 PM
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRA

Kailera Therapeutics Inc

Upgrade your Finviz experience